natgillin/translations-raw huggingface dataset:
Patients should notify their physician if they become pregnant during treatment with ACOMPLIA.
Če bolnica med zdravljenjem z zdravilom ACOMPLIA zanosi, mora o tem obvestiti zdravnika.
Patients should notify their physician if they become pregnant during treatment with ZIMULTI.
Če bolnica med zdravljenjem z zdravilom ZIMULTI zanosi, mora o tem obvestiti zdravnika.
Patients should only swallow ADROVANCE whole.
Bolnik mora pogoltniti celo tableto ADROVANCE.
Patients should only swallow FOSAVANCE whole.
Bolnik mora pogoltniti celo tableto FOSAVANCE.
Patients should only swallow VANTAVO whole.
Bolnik mora pogoltniti celo tableto VANTAVO.
Patients should pay particular attention to and be able to comply with the dosing instructions (see section 4.2).
Bolniki morajo biti posebno previdni in morajo biti sposobni slediti navodilom za odmerjanje (glejte poglavje 4.2).
Patients should receive adequate antithrombotic prophylaxis, as thrombotic and vascular events may occur in surgical patients, especially in those with underlying cardiovascular disease.
Bolniki morajo prejeti ustrezno antiagregacijsko profilakso, zaradi tveganja za trombotične in žilne dogodke pri kirurških bolnikih, še posebej pri tistih z boleznijo srca in ožilja.
Patients should receive an antihistamine to prevent an allergic reaction around 30 minutes before each dose of Torisel.
Bolniki morajo približno 30 minut pred vsakim odmerkom zdravila Torisel prejeti antihistaminik za preprečitev alergijskih reakcij.
Patients should receive calcium and vitamin D supplements if they do not get enough from their diet.
Bolniki morajo jemati tudi dodatek kalcija in vitamina D, če ju ne dobivajo dovolj s prehrano.
Patients should receive intravenous fluids throughout the 5 day clofarabine administration period to reduce the effects of tumour lysis and other events.
Za zmanjšanje učinkov tumorske lize in drugih dogodkov naj bolniki med 5-dnevnim obdobjem prejemanja klofarabina dobivajo intravenske tekočine.
Patients should receive one 200 mg tablet in the morning and either two 200 mg or one 400 mg tablet in the evening.
Bolniki naj vzamejo eno 200 mg tableto zjutraj in dve 200 mg tableti ali eno 400 mg tableto zvečer.
Patients should receive supplemental calcium and / or vitamin D if dietary intake is inadequate (see section 4.4 and section 4.5).
Če vnos s hrano ni zadosten, morajo bolniki prejemati dodatke kalcija, vitamina D ali obojega (glejte poglavje 4.4 in poglavje 4.5).
patients should receive the lower dose of apixaban 2.5 mg twice daily. patients with serum creatinine ≥ 1.5 mg/dL (133 micromole/L) associated with age
bolniki prejemati manjši odmerek apiksabana, in sicer 2,5 mg dvakrat na dan. bolniki s serumsko koncentracijo kreatinina ≥ 1,5 mg/dl (133 mikromolov/l) ter s starostjo
Patients should receive this information when starting Tysabri, when continuing treatment for longer than 2 years, and when stopping treatment, as the risk of PML persists for 6 months after stopping treatment.
Bolniki morajo te informacije dobiti na začetku zdravljenja z zdravilom Tysabri, če zdravljenje traja več kot dve leti in ob prenehanju zdravljenja, saj tveganje za pojav PML obstaja še šest mesecev po prenehanju zdravljenja.
Patients should remain under clinical supervision for a prolonged period of time (for several hours), following at least the first 2 infusions, taking into account the possibility of a late onset reaction.
Upoštevaje možnost reakcij s poznim začetkom morajo bolniki ostati pod kliničnim nadzorom daljši čas (vsaj nekaj ur ), vsaj po prvih 2 infundiranjih.
Patients should seek immediate medical attention if developing symptoms of serious allergic reactions (see section 4.4).
V primeru pojava simptomov resne alergijske reakcije, morajo bolniki nemudoma poiskati zdravniško pomoč (glejte poglavje 4.4).
Patients should show this card to their partner or carer, as well as to other doctors treating them, because they may notice symptoms of PML that the patient is not aware of, such as changes in mood, behaviour or speech.
Bolniki naj to kartico pokažejo partnerju, negovalcu ali drugim izbranim zdravnikom, saj lahko ti opazijo simptome progresivne multifokalne levkoencefalopatije, ki se jih bolnik ne zaveda, kot so spremembe razpoloženja, vedenja ali govora.
Patients should start with the low dose of
Bolniki morajo pri prvem vdihavanju uporabiti nizki
Patients should swallow the film-coated tablets with water.
Filmsko obložene tablete mora bolnik pogoltniti z vodo.
Patients should take calcium and vitamin D supplements while being treated with Xgeva.
Med zdravljenjem z zdravilom Xgeva morajo bolniki jemati dodatke kalcija in vitamina D.
Patients should take Invega either with or without food, but should not switch between taking it with food on one day and without food on another.
Bolniki naj jemljejo zdravilo Invega bodisi s hrano bodisi brez nje, vendar vsak dan enako, tj. da ga ne jemljejo enkrat s hrano, naslednji dan pa brez nje.
Patients should take Renagel with meals and adhere to their prescribed diets.
Bolniki morajo jemati zdravilo Renagel ob obroku in se držati predpisanih diet.
Patients should take sevelamer hydrochloride with meals and adhere to their prescribed diets.
Bolniki morajo jemati sevelamerijev klorid ob obroku in se držati predpisanih diet.
Patients should take the medicine regularly and avoid missing doses.
Zdravilo morajo bolniki jemati redno in paziti, da ne pozabijo vzeti odmerka.
Patients should take trametinib as monotherapy or in combination with dabrafenib at least one hour prior to or two hours after a meal due to the effect of food on trametinib absorption (see section 4.2 and 5.2).
Bolniki morajo trametinib, bodisi v monoterapiji ali v kombinaciji z dabrafenibom, vzeti vsaj eno uro pred jedjo ali vsaj dve uri po jedi, ker hrana vpliva na absorpcijo trametiniba (glejte poglavji 4.2 in 5.2).
Patients should tell their doctor immediately if they have symptoms that might be due to an infection, such as fever, sore throat and flu-like symptoms.
Bolniki morajo nemudoma obvestiti zdravnika o simptomih, ki bi lahko bili posledica okužbe, kot npr. vročina, vneto grlo in gripi podobni simptomi.
Patients should therefore be observed for several hours after at least the first two infusions and Benlysta should
Zato je treba po vsaj dveh prvih infuzijah bolnike
Patients should use a bronchodilator before each dose of Cayston.
Pred vsakim odmerkom zdravila Cayston morajo bolniki uporabiti bronhodilatator.
patients should use an alternative
morajo bolnice uporabljati drugo
Patients should usually start with two doses of 2.25 g (4.5 ml) per day.
Bolniki običajno začnejo z dvema odmerkoma po 2,25 g (4,5 ml) dnevno.
Patients should wait at least 4 hours after a dose before treating another BTP episode with PecFent.
Bolniki morajo počakati vsaj 4 ure po odmerku, preden vzamejo nov odmerek zdravila PecFent za zdravljenje naslednje epizode BTP.
Patients should wait at least 4 hours before treating another breakthrough pain episode with Instanyl during both titration and maintenance therapy.
Bolniki morajo počakati vsaj 4 ure pred začetkom zdravljenja naslednje epizode prebijajoče bolečine z zdravilom Instanyl, tako v obdobju titracije kot tudi med vzdrževalnim zdravljenjem.
Patients showing clinical response at Week 6 were required to begin corticosteroid tapering.
Bolniki, ki so dosegli klinični odziv, so v 6. tednu morali začeti z režimom zmanjševanja odmerka kortikosteroida.
Patients showing lack of response (lack of complete haematological response (CHR) at 6 months, increasing WBC, no major cytogenetic response (MCyR) at 24 months), loss of response (loss of CHR or MCyR) or severe intolerance to treatment were allowed to cross over to the alternative treatment arm.
Bolnikom, pri katerih se je pokazala odsotnost odziva (odsotnost popolnega hematološkega odziva (CHR - complete haematological response) pri mesecih, povečanje WBC, odsotnost pomembnega citogenetičnega odziva (MCyR - major cytogenetic response) pri 24 mesecih), izguba odziva (izguba CHR ali MCyR) ali težko neprenašanje zdravljenja, je bilo dovoljeno preiti na krak alternativnega zdravljenja.
Patients stabilised on one nebuliser should not switch to another nebuliser without close supervision by the treating doctor as different nebulisers have been shown to produce aerosols with slightly different physical characteristics and may have faster delivery of the solution (see section 5.2 of the Summary of Product Characteristics).
Bolniki, pri katerih je stanje stabilno ob uporabi enega nebulatorja, ne smejo preiti na drug nebulator, če tega skrbno ne nadzoruje lečeči zdravnik, saj se je pokazalo, da različni nebulatorji ustvarjajo aerosole z nekoliko drugačnimi fizikalnimi lastnostmi in lahko hitreje dovajajo raztopino (glejte poglavje 5.2 Povzetka glavnih značilnosti zdravila).
Patients stabilised on one nebuliser should not switch to another nebuliser without supervision by the treating physician as different nebulisers have been shown to produce aerosols with slightly different physical characteristics and delivery of the solution that may be faster (see section 5.2).
Bolniki, pri katerih je stanje stabilno ob uporabi enega nebulatorja, ne smejo preiti na drug nebulator, če tega ne nadzoruje lečeči zdravnik, saj se je pokazalo, da različni nebulatorji ustvarjajo aerosole z nekoliko drugačnimi fizikalnimi lastnostmi in lahko hitreje dovajajo raztopine (glejte poglavje 5.2).
Patients stable on ritonavir-boosted Invirase and requiring concomitant medication with potential to increase the exposure of saquinavir or patients on medication with potential to increase the exposure of saquinavir and requiring concomitant ritonavir-boosted Invirase where no alternative therapy is available and the benefits outweigh the risks:
Bolniki, ki so z zdravilom Invirase s podporno terapijo z ritonavirjem stabilni in potrebujejo sočasno zdravljenje z zdravilom, ki potencialno poveča izpostavljenost sakvinavirju, ali bolniki z zdravilom, ki potencialno poveča izpostavljenost sakvinavirju in potrebujejo sočasno zdravljenje z zdravilom Invirase s podporno terapijo z ritonavirjem, kjer ni na voljo drugo zdravljenje in korist pretehta tveganje: pred uvedbo sočasne terapije je treba napraviti EKG: bolniki z intervalom QT
Patients started on EXUBERA must receive comprehensive instructions in the use of the inhaler (see IFU).
Bolniki, ki jih začnete zdraviti z zdravilom EXUBERA, morajo prejeti izčrpna navodila o uporabi insulinskega inhalatorja (glejte Navodila za uporabo insulinskega inhalatorja).
Patients suffering from acute coronary syndrome:
Z akutnim koronarnim sindromom:
Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
bolnikih z miokardnim infarktom (od nekaj dni do manj kot 35 dni), ishemično kapjo (od 7 dni do manj kot 6 mesecev) ali dokazano periferno arterijsko boleznijo.
Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
Miokardnim infarktom (od nekaj dni do manj kot 35 dni), ishemično kapjo (od 7 dni do manj kot 6 mesecev) ali dokazano periferno arterijsko boleznijo.
Patients switching from immediate-release (Byetta) to prolonged-release (Bydureon) exenatide, may experience transient elevations in blood glucose concentrations, which generally improve within the first two weeks after initiation of therapy.
Bolniki, ki prehajajo od uporabe eksenatida v obliki s takojšnim sproščanjem (zdravilo Byetta) k eksenatidu v obliki s podaljšanim sproščanjem (zdravilo Bydureon), lahko občutijo prehodno zvišanje koncentracije glukoze v krvi, kar se navadno izboljša v prvih dveh tednih po začetku zdravljenja.
Patients switching from immediate-release (Byetta) to prolonged-release exenatide may experience transient elevations in blood glucose concentrations, which generally improve within the first two weeks after initiation of therapy.
Bolniki, ki prehajajo od uporabe eksenatida v obliki s takojšnim sproščanjem (zdravilo Byetta) k eksenatidu v obliki s podaljšanim sproščanjem (zdravilo Bydureon), lahko občutijo prehodno zvišanje koncentracije glukoze v krvi, kar se navadno izboljša v prvih dveh tednih po začetku zdravljenja.
Patients switching from more than once-daily basal or premix insulin therapy can be converted unit- to-unit to twice-daily Ryzodeg at the same total insulin dose as the patient’s previous total daily insulin dose.
Odmerek bolnikov, ki prehajajo z bazalnega insulinskega zdravljenja ali insulinskega zdravljenja s pripravljeno mešanico večkrat dnevno, lahko pretvorimo v odmerek zdravila Ryzodeg dvakrat na dan, v razmerju enot ena proti ena, pri čemer je celotni dnevni odmerek zdravila Ryzodeg enak celotnemu dnevnemu odmerku prej uporabljanega insulina.
Patients switching from once-daily basal or premix insulin therapy can be converted unit-to-unit to once-daily Ryzodeg at the same total insulin dose as the patient’s previous total daily insulin dose.
Odmerek bolnikov, ki prehajajo z bazalnega insulinskega zdravljenja ali insulinskega zdravljenja s pripravljeno mešanico enkrat dnevno, lahko pretvorimo v odmerek zdravila Ryzodeg enkrat na dan, v razmerju enot ena proti ena, pri čemer je celotni dnevni odmerek zdravila Ryzodeg enak celotnemu dnevnemu odmerku prej uporabljanega insulina.
Patients switching from separate tablets of dapagliflozin (10 mg total daily dose) and metformin to Ebymect should receive the same daily dose of dapagliflozin and metformin already being taken or the nearest therapeutically appropriate dose of metformin.
Bolniki, ki prehajajo z ločenih tablet dapagliflozina (celokupni dnevni odmerek 10 mg) in metformina na zdravilo Ebymect, morajo dobiti enak dnevni odmerek dapagliflozina in metformina, kot ga že jemljejo, ali najbližji terapevtsko ustrezni odmerek metformina.
Patients switching from separate tablets of dapagliflozin (10 mg total daily dose) and metformin to Xigduo should receive the same daily dose of dapagliflozin and metformin already being taken or the nearest therapeutically appropriate dose of metformin.
Bolniki, ki prehajajo z ločenih tablet dapagliflozina (celokupni dnevni odmerek 10 mg) in metformina na zdravilo Xigduo, morajo dobiti enak dnevni odmerek dapagliflozina in metformina, kot ga že jemljejo, ali najbližji terapevtsko ustrezni odmerek metformina.
Patients switching from separate tablets of saxagliptin and metformin should receive the doses of saxagliptin and metformin already being taken.
Bolniki, ki prehajajo z ločenih tablet saksagliptina in metformina, morajo prejeti saksagliptin in metformin v odmerkih kot ju že jemljejo.
Patients switching from Viramune immediate-release to Viramune prolonged-release
Bolniki, ki so prešli z zdravila Viramune s takojšnjim sproščanjem na zdravilo Viramune s podaljšanim sproščanjem
Patients switching immediately from treatment with another protease inhibitor taken with ritonavir or from a non-nucleoside reverse transcriptase inhibitor based regimen, without a wash-out period, should however initiate and continue Invirase at the standard recommended dose of 1000 mg two times daily with ritonavir 100 mg two times daily.
Bolniki, ki zamenjajo zdravljenje in takoj, brez obdobja izpiranja, preidejo iz zdravljenja z drugim zaviralcem proteaze v kombinaciji z ritonavirjem ali z nenukleozidnim zaviralcem reverzne transkriptaze, bi morali začeti in nadaljevati z zdravilom Invirase v standardnem priporočenem odmerku 1000 mg dvakrat na dan z ritonavirjem 100 mg dvakrat na dan.
Patients take a daily maintenance dose of DuoResp Spiromax and in addition take DuoResp Spiromax as needed in response to symptoms.
Bolniki redno jemljejo dnevni vzdrževalni odmerek zdravila DuoResp Spiromax, ob pojavu simptomov pa po potrebi dodatne odmerke zdravila DuoResp Spiromax.
Patients taking a minimum of 30 morphine equivalent units (meu) of opioids per day for at least 4 weeks before enrolment and self-reported OIC were eligible.
Za vključitev so bili primerni bolniki, ki so pred vključitvijo vsaj 4 tedne jemali najmanj 30 morfinskih ekvivalentnih enot opioidov in so imeli po lastni navedbi OIC.
patients taking another antiviral medicine called telbivudine;
bolnikih, ki jemljejo drugo protivirusno zdravilo, imenovano telbivudin;
Patients taking beta-blockers
Bolniki, ki jemljejo beta-blokatorje
Patients taking beta-blockers
Bolniki, ki jemljejo blokatorje beta
Patients taking concomitant ACE inhibitor (e.g. ramipril) therapy may be at increased risk for angioedema (e.g. swelling of the airways or tongue, with or without respiratory impairment) (see section 4.5).
Pri bolnikih, ki se sočasno zdravijo z zaviralci angiotenzinske konvertaze (na primer z ramiprilom) je tveganje za pojav angioedema večje (na primer otekanje dihalnih poti ali jezika, z oteženim dihanjem ali brez njega) (glejte poglavje 4.5).
Patients taking concomitant ACE inhibitor (e.g. ramipril) therapy may be at increased risk for angioedema (see section 4.4).
Pri bolnikih, ki se sočasno zdravijo z zaviralci angiotenzinske konvertaze (na primer z ramiprilom) je tveganje za pojav angioedema večje (glejte poglavje 4.4).
Patients taking concomitant ACE inhibitor (e.g. ramipril) therapy may be at increased risk for angioedema (see section 4.4).
Pri bolnikih, ki se sočasno zdravijo z zaviralci angiotenzinske konvertaze (na primer z ramiprilom), je tveganje za pojav angioedema večje (glejte poglavje 4.4).
Patients taking concomitant anticoagulation, such as warfarin or phenprocoumon should be monitored regularly for changes in prothrombin time, international normalized ratio (INR), and clinical bleeding episodes.
Bolnike, ki sočasno jemljejo antikoagulante, kot sta varfarin ali fenprokoumon, je treba redno spremljati glede sprememb protrombinskega časa, mednarodnega umerjenega razmerja (international normalized ratio – INR) in kliničnih epizod krvavitev.
Patients taking coumarin- derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR) and the anti-coagulant dose adjusted accordingly.
Bolnike, ki jemljejo antikoagulante kumarinskega tipa sočasno s kapecitabinom, moramo pazljivo spremljati in meriti njihove koagulacijske parametre (protrombinski čas ali INR) ter odmerek antikoagulanta ustrezno prilagajati.
Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR) and the anti-coagulant dose adjusted accordingly.
Bolnike, ki jemljejo antikoagulante kumarinskega tipa sočasno s kapecitabinom, moramo pazljivo spremljati in meriti njihove koagulacijske parametre (protrombinski čas ali INR) ter odmerek antikoagulanta ustrezno prilagajati.
Patients taking Cystadane appeared to have greater reductions in homocysteine levels than untreated patients.
Pri bolnikih, ki so prejemali zdravilo Cystadane, je, kot kaže, prišlo do večjega znižanja ravni homocisteina kot pri nezdravljenih bolnikih.
Patients taking Efient should also take aspirin as prescribed by their doctors.
Bolniki, ki jemljejo zdravilo Efient, morajo prav tako jemati aspirin, in sicer v odmerku, ki jim ga je predpisal zdravnik.
Patients taking Ferriprox, or their carers, must be given a reminder card with information on how to take the medicine safely.
Bolniki, ki jemljejo zdravilo Ferriprox, ali njihovi skrbniki, morajo prejeti opozorilno kartico z informacijami o varnem jemanju zdravila.
Patients taking Ilaris in part II had a 64% reduced risk of a flare event as compared to the placebo group (hazard ratio of 0.36; 95% CI: 0.17 to 0.75; p=0.0032).
Pri bolnikih, ki so v 2. obdobju prejemali zdravilo Ilaris, je bilo tveganje za dogodke, ki pomenijo zagon bolezni, nižje za 64 % v primerjavi z bolniki v skupini s placebom (razmerje ogroženosti je bilo 0,36; 95-odstotni IZ: 0,17 do 0,75; p=0,0032).
Patients taking Inovelon had a 35.8% reduction in the total number of seizures, falling from an average of 290 seizures in the four- week period before Inovelon was started.
Pri bolnikih, ki so jemali zdravilo Inovelon, so opazili zmanjšanje števila vseh napadov za 35,8 % od povprečno 290 napadov v štirih tednih pred začetkom jemanja zdravila Inovelon.
Patients taking levodopa (advanced stage of Parkinson’s disease)
Bolniki, ki jemljejo L-dopo (napredovana faza Parkinsonove bolezni)
patients taking metformin as an add-on to other diabetes medicines, including insulin, when combinations of these with metformin alone are insufficient; patients who are already taking metformin and empagliflozin as separate tablets.
bolnikih, ki jemljejo metformin kot dodatek drugim zdravilom za zdravljenje sladkorne bolezni, vključno z insulinom, kadar kombinacije s samostojnim metforminom niso zadostne; bolnikih, ki že jemljejo metformin in empagliflozin v obliki ločenih tablet.
Patients taking nucleoside reverse transcriptase inhibitor (NRTI) treatment in association with ribavirin and interferon alfa-2b may be at increased risk of mitochondrial toxicity, lactic acidosis and hepatic decompensation (see section 4.4).
Bolniki, ki prejemajo terapijo z nukleozidnim zaviralcem reverzne transkriptaze (NRTI- nucleoside reverse transcriptase inhibitor) skupaj z ribavirinom in interferonom alfa-2b, imajo lahko povečano tveganje za nastanek toksičnosti za mitohondrije, laktacidoze in jetrne dekompenzacije (glejte poglavje 4.4).
Patients taking nucleoside reverse transcriptase inhibitor (NRTI) treatment in association with ribavirin and interferon alfa-2b may be at increased risk of mitochondrial toxicity, lactic acidosis and hepatic decompensation (see section 4.4).
Bolniki, ki prejemajo terapijo z nukleozidnim zaviralcem reverzne transkriptaze (NRTI-nucleoside reverse transcriptase inhibitor) skupaj z ribavirinom in interferonom alfa-2b, imajo lahko povečano tveganje za nastanek toksičnosti za mitohondrije, laktacidoze in jetrne dekompenzacije (glejte poglavje 4.4).
Patients taking Orencia also had a greater improvement in physical function after six months.
Pri bolnikih, ki so prejemali zdravilo Orencia, je bilo po šestih mesecih opaženo tudi večje izboljšanje fizične funkcije.
patients taking potassium-
bolnikih, ki prejemajo diuretike, ki varčujejo s
Patients taking Rapamune should discontinue breast-feeding.
Bolnice, ki jemljejo zdravilo Rapamune, morajo prenehati z dojenjem.
Patients taking Renvela should adhere to their prescribed diets.
Bolniki, ki jemljejo zdravilo Renvela se morajo držati predpisane diete.
Patients taking Renvela should adhere to their prescribed diets.
Bolniki, ki jemljejo zdravilo Renvela, morajo uživati predpisano dieto.
Patients taking Renvela should adhere to their prescribed diets.
Bolniki, ki jemljejo zdravilo Renvela, se morajo držati predpisane diete.
Patients taking rifampicin (an antibiotic) may need to take a higher dose of Stocrin.
Odmerek zdravila Stocrin je treba
Patients taking Sevelamer carbonate Zentiva should adhere to their prescribed diets.
Bolniki, ki jemljejo zdravilo Sevelamer carbonate Zentiva se morajo držati predpisane diete.
Patients taking Sevelamer carbonate Zentiva should adhere to their prescribed diets.
Bolniki, ki jemljejo zdravilo Sevelamer carbonate Zentiva, morajo uživati predpisano dieto.
Patients taking Sevelamer carbonate Zentiva should adhere to their prescribed diets.
Bolniki, ki jemljejo zdravilo Sevelamer carbonate Zentiva, se morajo držati predpisane diete.
Patients taking the oral solution, particularly those with renal impairment or with decreased ability to metabolise propylene glycol (e.g. those of Asian origin), should be monitored for adverse reactions potentially related to propylene glycol toxicity (i.e. seizures, stupor, tachycardia, hyperosmolarity, lactic acidosis, renal toxicity, haemolysis) (see section 4.3).
Bolnike, ki uporabljajo peroralno raztopino, zlasti tiste z okvaro ledvic ali slabšo zmožnostjo za presnovo propilenglikola (npr. tiste azijskega porekla), je treba nadzirati glede neželenih učinkov, ki so lahko povezani s toksičnostjo propilenglikola (t.j. konvulzivnih napadov, stuporja, tahikardije, hiperosmolarnosti, laktacidoze, ledvične toksičnosti, hemolize) (glejte poglavje 4.3).